Indications for Adalimumab

Adalimumab (Adalimumab) is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults 2 years and older with moderate Patients with to severely active polyarticular juvenile idiopathic arthritis (JIA) treated with monotherapy or in combination with methotrexate; adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), moderately to severely active ulcerative colitis ( UC); moderately to severely active Crohn's disease (CD) in adult and pediatric patients 6 years of age and older; moderate to severe chronic plaque psoriasis in adult candidates receiving systemic therapy or phototherapy, and when other systemic therapies are less medically appropriate.